Jan 26, 2026 | Drugmakers, Group purchasing organization (GPO), Pharmacy Benefits Manager (PBM), Rebates
An extensive investigation by Hunterbrook Media sheds new light on how the nation’s three largest PBMs may be using little-known affiliated entities – effectively middlemen to the middlemen — to quietly retain billions of dollars that employers and health plans never...
Dec 29, 2025 | MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rebates, Rx Costs, Transparency
While the major PBMs still dominate the market, their grip is loosening. A recent Pulse of the Purchaser survey found that the percentage of employers contracted with one of the Big 3 dropped from 72% in 2024 to 61% by late 2025, as more organizations shifted toward...
Aug 25, 2025 | Cost Savings, Drug costs, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rebates, Rx Costs, Transparency
A new paper from the American Medical Association (AMA) has found that the pharmacy benefit manager (PBM) marketplace remains highly concentrated, with just a few major players controlling most of the activity. Many of these PBMs are vertically integrated with health...
Jul 1, 2025 | Cost Savings, Drug costs, GLP-1s, MedBen Rx, Ozempic, Rebates, Rx Costs, Specialty Drugs, Wegovy, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
Oct 28, 2024 | Federal Trade Commission (FTC), Pharmacy, Pharmacy Benefits Manager (PBM), Rebates, Spread Pricing
KFF Health News reports on the disparity between pharmacy benefit manager (PBM) payments to large pharmacy chains compared to small drugstores: “[An American Pharmacy Cooperative] analysis early this year showed chains were paid well beyond the family business...
Sep 27, 2024 | Drug advertising, Drug costs, Pharmacy, Rebates, Study
KFF Health News warns consumers not to take TV drug ads at face value: “A 2023 study found that, among top-selling drugs, those with the lowest levels of added benefit tended to spend more on advertising to patients than doctors. ‘I worry that...
